Yes, in the ASM meeting Pourhassan updates the num

Yes, in the ASM meeting Pourhassan updates the number of deaths to 50 if you assume it was intelligible.

The critical number is how many deaths within the 28 day measuring period for the 195 interim analysis patients. This critical number will have a great influence on the p-value in the interim analysis.

Any other death, any death outside of the 195 interim analysis patients in the 28 day measuring, does not become critically important until two months from now when the trial concludes.

At this moment, I am interested in the chances for an efficacy stop from the interim analysis. The efficacy stop opportunity is a relatively strong function of the number of deaths in the interim analysis.

Pourhassan doesnt seem to care one way or another whether the deaths are in the interim or not. He makes no effort to articulate the distinction.

Probably because he figures he will not get an efficacy stop even with a very low p-value.